Clin Case Rep Int | Volume 5, Issue 1 | Case Report | Open Access

The Administration of Tocilizumab to a COVID-19 Patient with Psoriasis Vulgaris – A Case Report

Marija Branković1*, Igor Jovanović2 , Tijana Radonjić2 , Ilija Bukurecki2 and Marija Zdravković1

1 University Hospital Medical Center Bezanijska Kosa, Serbia 2 University of Belgrade, Serbia

*Correspondance to: Marija Branković 

Fulltext PDF

Abstract

A case of male patient admitted to a hospital with bilateral pneumonia caused by COVID-19 is presented. It was found on admission that the patient had had psoriasis vulgaris; the patient had no therapy for six years and he had no regular checkups. Due to progression and high CT scan severity score and elevated serum IL-6, the decision was made to administer the patient tocilizumab. Upon administration, psoriatic lesions were in retreat. Even though there are some reports describing tocilizumab induced psoriasis, some studies have demonstrated a high level of IL-6 in psoriatic plaques. Therefore, therapies that disrupt IL-6 signaling could be a treatment option for psoriasis.

Keywords:

Covid-19; Covid; Corona Virus; Coronavirus disease 2019

Citation:

Branković M, Jovanović I, Radonjić T, Bukurecki I, Zdravković M. The Administration of Tocilizumab to a COVID-19 Patient with Psoriasis Vulgaris – A Case Report. Clin Case Rep Int. 2021; 5: 1226..

Subscribe to Our Newsletter